BC Extra | Jul 31, 2019
Company News

July 31 Company Quick Takes: Bayer, Orion win approval in prostate cancer; plus Keytruda, Roche-Spark, UC v. Broad and more

Bayer, Orion androgen receptor inhibitor approved for prostate cancer  FDA approved an NDA for Nubeqa darolutamide from Bayer AG (Xetra:BAYN) and Orion Corp. (HSE:ORNAV; HSE:ORNBV) to treat non-metastatic castration-resistant prostate cancer. The oral androgen receptor...
BC Week In Review | Aug 17, 2015
Company News

Alligator Bioscience, J&J deal

Alligator granted Johnson & Johnson’s Janssen Biotech Inc. unit exclusive, worldwide rights to develop and commercialize ADC-1013 . Alligator expects to complete a Phase I trial of the antibody-based CD40 receptor activator immunotherapy in solid tumors...
BC Extra | Aug 13, 2015
Company News

Janssen snaps up Alligator's immunotherapy candidate

Alligator Bioscience AB (Lund, Sweden) granted the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) exclusive, worldwide rights to cancer immunotherapy candidate ADC-1013 . Under a separate agreement, J&J's venture arm Johnson & Johnson Innovation-JJDC...
BC Week In Review | Jun 9, 2014
Company News

Alligator Bioscience, BioInvent deal

BioInvent sold back all rights to preclinical cancer compound ADC-1013 to former partner Alligator for an undisclosed sum. BioInvent has successfully manufactured the antibody-based CD40 receptor activator immunotherapy and will fulfill the remaining activities required...
Items per page:
1 - 4 of 4